Innovus Pharmaceuticals (Innovus Pharmaceuticals) Accounts Receivable : $0.12 Mil (As of Sep. 2019)

View and export this data going back to 2008. Start your Free Trial

What is Innovus Pharmaceuticals Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Innovus Pharmaceuticals's accounts receivables for the quarter that ended in Sep. 2019 was $0.12 Mil.

Accounts receivable can be measured by Days Sales Outstanding. Innovus Pharmaceuticals's Days Sales Outstanding for the quarter that ended in Sep. 2019 was 1.86.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Innovus Pharmaceuticals's Net-Net Working Capital per share for the quarter that ended in Sep. 2019 was $-3.67.

Innovus Pharmaceuticals Accounts Receivable Historical Data

The historical data trend for Innovus Pharmaceuticals's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innovus Pharmaceuticals Accounts Receivable Chart

Innovus Pharmaceuticals Annual Data

Trend

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Accounts Receivable

Get a 7-Day Free Trial

0.19

0.08

0.03

0.07

0.28

Innovus Pharmaceuticals Quarterly Data
	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19
Accounts Receivable	Get a 7-Day Free Trial															0.36	0.28	0.13	0.32	0.12

Innovus Pharmaceuticals Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.

Innovus Pharmaceuticals Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

Innovus Pharmaceuticals's Days Sales Outstanding for the quarter that ended in Sep. 2019 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0.117	/	5.755	*	91
=	1.86

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Innovus Pharmaceuticals's accounts receivable are only considered to be worth 75% of book value:

Innovus Pharmaceuticals's Net-Net Working Capital Per Share for the quarter that ended in Sep. 2019 is calculated as:

	Net-Net Working Capital Per Share
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(0.955	+	0.75 * 0.117	+	0.5 * 1.742	-	11.51
-	0	-	0)	/	2.61238
=	-3.67

Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.

Innovus Pharmaceuticals Accounts Receivable Related Terms

Thank you for viewing the detailed overview of Innovus Pharmaceuticals's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

Innovus Pharmaceuticals (Innovus Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Innovus Pharmaceuticals Inc (OTCPK:INNV) » Definitions » Accounts Receivable

Comparable Companies

Traded in Other Exchanges

N/A

Address

8845 Rehco Road, San Diego, CA, USA, 92121

Website

http://www.innovuspharma.com

Innovus Pharmaceuticals Inc is engaged in the healthcare industry. It is a specialty pharmaceutical company engaged in the commercialization, licensing and development of safe and effective non-prescription medicine and consumer care products to improve men's and women's health and vitality and respiratory diseases. Innovus distributes OTC medicines and consumer and health products directly, through commercial partners to primary care physicians, urologists, gynecologists and therapists, and directly to consumers through its on-line channels, retailers, and wholesalers.

Executives

Armistice Capital, Llc	10 percent owner	510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Armistice Capital Master Fund Ltd.	10 percent owner	C/O ARMISTICE CAPITAL, LLC, 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Steven Boyd	10 percent owner	510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Vivian H Liu	director
Henry Jemil Esber	director	38 ANGELL BROOK DRIVE, WEST BOYLSTON MA 01853
Randy Berholtz	officer: EVP, CORPORATE DEVELOPMENT	6330 NANCY RIDGE DRIVE, SUITE 103, SAN DIEGO CA 92121
Ryan J Selhorn	officer: VP, CFO	4275 EXECUTIVE SQUARE, SUITE 650, LA JOLLA CA 92037
Bassam Damaj	director, officer: CHIEF EXECUTIVE OFFICER	C/O BIO-QUANT, INC., 6330 NANCY RIDGE DRIVE, SUITE 103, SAN DIEGO CA 92121
Robert Hoffman	officer: Chief Financial Officer	ARENA PHARMACEUTICALS INC, 6166 NANCY RIDER DRIVE, SAN DIEGO CA 92121
Morgan R Brown	officer: See remarks	420 CHIPETA WAY, SALT LAKE CITY UT 84108
Jacki Bartholomew	director	175 SOUTH MAIN STREET, NO 1212, SALT LAKE CITY UT 84111
Thomas L Harkness	director, officer: Secretary	175 SOUTH MAIN STREET, NO 1212, SALT LAKE CITY UT 84111
Wallace Boyack	director, 10 percent owner, officer: President & CEO	175 S MAIN ST, NO 1212, SALT LAKE CITY UT 84111